Gilead Sciences, Inc. (Nasdaq: GILD) has released new data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), highlighting the efficacy and safety of lenacapavir, an injectable HIV-1 capsid inhibitor, for HIV prevention among a diverse group of cisgender men…
A team of researchers from City of Hope® and The University of Texas M.D. Anderson Cancer Center has shared promising safety and efficacy results from a Phase 1 trial involving a personalized vaccine for lymphoplasmacytic lymphoma, a rare and slow-growing…
The report titled “CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027” has been added to ResearchAndMarkets.com’s offerings. CD137, also known as 4-1BB, has emerged as a promising target in cancer immunotherapy. Its potential lies in its ability to stimulate…
PharmaLegacy Laboratories, a leading provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO). This acquisition marks a significant milestone for PharmaLegacy as it strengthens its global…
Jackson Egen discovered the significance of fundamental lab research during his graduate studies at UC Berkeley in the 1990s, working under the guidance of esteemed immunologist James Allison. “Jim emphasized that more effective cancer immunotherapies could arise from a deep…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced that it will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024, taking place from September 13-17, 2024, in Barcelona, Spain. The presentations will highlight advancements in solid tumor…
Stolen contact lenses sold through fake online pharmacies, prescription medications missing active ingredients, and surgical sutures made from substandard materials are just a few examples of counterfeit healthcare products that plague the global market. This illicit industry generates an estimated…
OMNY Health, a leader in creating compliant cross-industry data partnerships, has announced the launch of its Glucagon-Like Peptide-1 (GLP-1) data network, reinforcing its mission to democratize healthcare data. This new network, encompassing over 600,000 patients, will empower OMNY’s partners in…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced the top-line results from a Phase 3 open-label, single-arm trial conducted in Japan. The study assessed the safety and efficacy of their cannabidiol oral solution, marketed globally as Epidiolex®/Epidyolex®, as an adjunctive treatment…
AstraZeneca’s IMFINZI® (durvalumab) Approved in the US for Comprehensive Treatment of Resectable Non-Small Cell Lung Cancer AstraZeneca has announced that IMFINZI® (durvalumab), in combination with chemotherapy, has received approval from the US Food and Drug Administration (FDA) for the treatment…
Agendia is pleased to announce that it has achieved certification from the European Union (EU) In Vitro Diagnostic Medical Device Regulation (IVDR) for three of its products: the MammaPrint® FFPE Microarray, BluePrint® FFPE Microarray, and the MammaPrint® and BluePrint® NGS…
BioNTech SE (Nasdaq: BNTX) today revealed top-line results from their Phase 3 clinical trial evaluating a combined mRNA vaccine candidate against influenza and COVID-19 in healthy adults aged 18-64. This combination vaccine includes Pfizer’s mRNA-based influenza candidate and the companies’…
